We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Using data from the National Diabetes Audit in England, the study authors assessed whether COVID-19–related mortality was associated with preinfection prescriptions of different classes of glucose-lowering drugs in individuals with T2D. Among the 2,851,465 individuals with T2D, 13,479 (0.5%) COVID-19 related deaths occurred (8.9 per 1000 person-years). Individuals who were prescribed metformin, SGLT2 inhibitors, and sulfonylureas had a lower risk of COVID-19–related mortality compared with individuals not prescribed the medication. Patients prescribed insulin and DPP-4 inhibitors had a higher risk of COVID-19–related mortality. However, in all comparisons, differences in risk were small and may have been due to confounding factors.
This study does not support changes to glucose-lowering drugs in the setting of the COVID-19 pandemic as differences in mortality risk were small and may have been due to confounding by indication.
In patients with type 2 diabetes, hyperglycaemia is an independent risk factor for COVID-19-related mortality. Associations between pre-infection prescription for glucose-lowering drugs and COVID-19-related mortality in people with type 2 diabetes have been postulated but only investigated in small studies and limited to a few agents. We investigated whether there are associations between prescription of different classes of glucose-lowering drugs and risk of COVID-19-related mortality in people with type 2 diabetes.
This was a nationwide observational cohort study done with data from the National Diabetes Audit for people with type 2 diabetes and registered with a general practice in England since 2003. Cox regression was used to estimate the hazard ratio (HR) of COVID-19-related mortality in people prescribed each class of glucose-lowering drug, with covariate adjustment with a propensity score to address confounding by demographic, socioeconomic, and clinical factors.
Among the 2 851 465 people with type 2 diabetes included in our analyses, 13 479 (0·5%) COVID-19-related deaths occurred during the study period (Feb 16 to Aug 31, 2020), corresponding to a rate of 8·9 per 1000 person-years (95% CI 8·7–9·0). The adjusted HR associated with recorded versus no recorded prescription was 0·77 (95% CI 0·73–0·81) for metformin and 1·42 (1·35–1·49) for insulin. Adjusted HRs for prescription of other individual classes of glucose-lowering treatment were as follows: 0·75 (0·48–1·17) for meglitinides, 0·82 (0·74-0·91) for SGLT2 inhibitors, 0·94 (0·82–1·07) for thiazolidinediones, 0·94 (0·89-0·99) for sulfonylureas, 0·94 (0·83–1·07) for GLP-1 receptor agonists, 1·07 (1·01–1·13) for DPP-4 inhibitors, and 1·26 (0·76–2·09) for α-glucosidase inhibitors.
Our results provide evidence of associations between prescription of some glucose-lowering drugs and COVID-19-related mortality, although the differences in risk are small and these findings are likely to be due to confounding by indication, in view of the use of different drug classes at different stages of type 2 diabetes disease progression. In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes.
Prescription of Glucose-Lowering Therapies and Risk of COVID-19 Mortality in People With Type 2 Diabetes: A Nationwide Observational Study in England
Lancet Diabetes Endocrinol 2021 Mar 30;[EPub Ahead of Print], K Khunti, P Knighton, F Zaccardi, C Bakhai, E Barron, N Holman, P Kar, C Meace, N Sattar, S Sharp, NJ Wareham, A Weaver, E Woch, B Young, J Valabhji